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Abstract 
Auranofin, an organogold compound classified as an anti-rheumatic agent is under phase 2 
clinical trials for re-purposing to treat recurrent epithelial ovarian cancer.  We have reported 
earlier that Breast cancer 1, early onset (BRCA1) mutant ovarian cancer cells exhibit increased 
sensitivity to auranofin. BRCA1 is a DNA repair protein whose functional status is critical in 
the prognosis of ovarian cancer. Apart from DNA repair capability of cancer cells, membrane 
fluidity is also implicated in modulating resistance to chemotherapeutics. We report here that 
membrane fluidity influences the sensitivity of ovarian cancer cell lines (OVCAR5 and 
IGROV1) to auranofin.  Electron spin resonance (ESR) analysis revealed a more fluidized 
membrane in IGROV1 compared to OVCAR5.  Interestingly, IGROV1 cells were more 
sensitive to auranofin induced cytotoxicity than OVCAR5. In comparison to OVCAR5, 
IGROV1 cells also exhibited an increased number of DNA double strand breaks (DSBs) upon 
auranofin treatment as assessed by 53BP1 immunostaining. Furthermore, correlation analysis 
demonstrated a strong positive correlation (r = 0.856) between membrane fluidity and 
auranofin sensitivity in these cell lines. Auranofin-treated IGROV1 cells were also exhibited 
increased cellular oxidation and apoptosis. Anti-oxidant, N-acetyl cysteine (NAC) inhibited 
the cellular oxidation and apoptosis in auranofin-treated ovarian cancer cells suggesting 
reactive oxygen species (ROS) mediates the anti-cancer properties of auranofin. Overall, our 
study suggests that auranofin mediates its cytotoxicity via ROS production in ovarian cancer 
cells which correlates positively with membrane fluidity.   
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Introduction 
The dynamic nature of plasma membrane inferred as membrane fluidity is a critical 
physiochemical property that modulates cellular functions. Over the years,  a significant 
number of studies have been undertaken to understand how membrane fluidity influences drug 
sensitivity in cancer cells (1). Analysis of membrane dynamics of chemo-resistant cancer cells 
reveals rigidification of cell membranes (2). The observed membrane rigidity of resistant 
cancer cells has been found to be due to the presence of relatively high amounts of cholesterol 
and sphingomyelin (3,4). Breast cancer cells were reported to have reduced expression of 
sphingomyelinase that catalyses the hydrolysis of sphingomyelin (5). Recovering 
sphingomyelinase expression fluidizes the membrane and enhances drug transport which 
eventually leads to reversal of resistance (6). Interestingly, the threshold concentration of 
internalised doxorubicin is the same for both resistant and sensitive cells suggesting drug 
uptake could be a major factor deciding the sensitivity of cancer cells (2). Modulation of 
membrane fluidity by pharmacological agents has been demonstrated to increase the drug 
uptake and thereby sensitivity of cancer cells to chemotherapeutic agents (7).  The membrane 
lipid analysis of cisplatin and doxorubicin resistant breast cancer cells showed a high content 
of cholesterol and sphingomyelins which results in membrane rigidity (4). Conversely, 
resistant cancer cells possess fewer amounts of diacyl and triacyl glycerols that are known to 
constitute a more fluid membrane (4). A similar analysis of membrane phospholipids 
demonstrated qualitative and quantitative differences between malignant, benign and normal 
breast tissues (3). Significantly distinguishable was lysophosphatidylcholine where its presence 
was remarkably decreased in malignant and benign tissues compared to normal breast tissues 
(3). However, a comparative study of membrane fluidity and drug sensitivity of cancer cells of 
the same histological origin has not yet been performed.  
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Auranofin, a thioredoxin reductase inhibitor has been widely used for the treatment of 
rheumatoid arthritis under the proprietary name Ridaura. Auranofin has also been demonstrated 
to possess anti-cancer properties in both in vitro and in vivo conditions (8,9). Moreover, 
auranofin is currently undergoing phase 2 clinical trials for re-purposing to treat recurrent 
epithelial ovarian cancer (https://clinicaltrials.gov/ct2/show/NCT01747798). We have recently 
reported that genetic depletion of BRCA1 sensitizes ovarian cancer cells to auranofin (10).  
Auranofin induces lethal DNA double strand breaks (DSBs) and apoptosis in BRCA1 deficient 
ovarian cancer cells (10).  Anti-oxidant mediated protection of BRCA1 deficient cells suggest 
that reactive oxygen species (ROS) plays a critical role in auranofin induced DNA damage and 
apoptosis (10).   
Membrane fluidity is often studied in association with intracellular drug uptake (2,7). However, 
early increase in membrane fluidity is critical in modulating cellular response to 
chemotherapeutic drugs such as cisplatin (11). Interestingly, blocking the early increase in 
membrane fluidity by pharmacological means inhibit apoptosis despite the intracellular uptake 
and formation of cisplatin DNA adducts (11). This suggests that changes in membrane fluidity 
induced by chemotherapeutic drugs may regulate cellular fate which is a critical and 
independent process from intracellular drug uptake and its targets. Furthermore, this also points 
that membrane fluidity is a critical physiochemical parameter that could potentially modulate 
multiple processes from drug entry to induced cellular outcome. However, a correlative study 
investigating the role of inherent membrane fluidity in regulating the genotoxic and cytotoxic 
effects of drugs has yet to be established. Adopting an integrated approach, in this study we 
therefore aimed to elucidate how plasma membrane fluidity could modulate cytotoxic and 
genotoxic responses of ovarian cancer cell lines (IGROV1 & OVCAR5) of adenocarcinoma 
origin to auranofin.  
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Materials and methods 
 Chemicals  
All chemicals were purchased from Sigma–Aldrich, UK unless indicated otherwise.  Anti-
53BP1 antibody (Rabbit polyclonal) was purchased from Novus Biologicals, UK. Rabbit 
polyclonal antibodies against PARP, Nrf2 and Actin were purchased from Cell Signalling 
Technology, Danvers, MA. Alexa Fluor 488-labelled anti-rabbit antibody was purchased from 
Molecular Probes, UK. 
 Cell culture and treatments 
 Ovarian cancer cell lines were a kind gift from Prof Hani Gabra, Hammersmith Hospital, 
Imperial College London, UK. Cells were maintained in RPMI-1640 (Gibco, Paisley, UK) 
and the medium was supplemented with 10 % fetal bovine serum (Gibco) 50 U/ml penicillin 
(Gibco) and 50 mg/ml streptomycin (Gibco) and maintained at 37 °C in a humidified 5 % 
CO2 atmosphere. Auranofin was purchased from Sigma-Adrich, UK. Auranofin is insoluble 
in water and soluble in highly polar organic solvents such as DMSO. A detailed chemical and 
physical properties is given in pubchem 
(https://pubchem.ncbi.nlm.nih.gov/compound/16667669#section=Experimental-Properties) 
For treatment with auranofin, a stock solution of 14.73 mM was made in DMSO. Final 
concentration (v/v) of DMSO in the experimental cell culture medium was 0.013 % for 
achieving 2 µM of auranofin. For concentration viability study, the concentration of DMSO 
(v/v) was 0.0678 % to achieve 10 µM of auranofin. Respective higher concentration (v/v) of 
DMSO was added to the control cells. For pre-treating cells with N-acetyl cysteine (NAC), 
NAC (2.5 mM) was added to the cells for 2 h before treating the cells with auranofin. 
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Determination of membrane fluidity 
Membrane fluidity was measured by Electron spin resonance (ESR) spectroscopy, using the 
spin label 5-doxyl stearic acid (5-DS). 2 µl of a 10-3 M solution of 5-DS in ethanol was 
introduced to an Eppendorf tube and the ethanol was evaporated by a stream of nitrogen to 
leave a film of the spin label. Approximately 106 cells in 1 ml phosphate buffered saline (PBS) 
were added to the tube and vortexed for 30 s to allow the label to be taken up by the cells. The 
cell pellet was washed with fresh PBS and re-suspended in 10-20 µl of PBS, before being 
sucked into a 5 cm length of gas permeable Teflon tubing (Zeus, Donegal, Ireland) which was 
folded in half and inserted into an open ended 4 mm i.d. quartz tube and positioned in the 
microwave cavity, where the temperature was controlled by a flow of air. Measurements were 
made using a Bruker EMXmicro ESR spectrometer (Coventry, UK). Measurement conditions 
were approximately 9.4 GHz microwave frequency, 10 mW microwave power, 3355 gauss 
magnetic field and sweep width 100 gauss. Spectra were collected with a time constant of 82 
ms. and sweep time of 110 s. The separation of the outer extrema (2Tǁǁ ) corresponds 
approximately to 2Tzz and that of the inner extrema (2T⊥ ) to approximately 2Tyy or 2Txx 
(Supplementary figure 1). As motional freedom increases, 2Tǁǁ decreases and 2T⊥ increases. In 
this intermediate to slow motion range, where the correlation time is between 2 x 10-7 and 3 x 
10-9 s, the rigidity of the label in a specific environment can be defined in terms of an order 
parameter, S, such that S=1 for a completely rigid system and S=0 for a completely fluid system. 
The order of a given environment is given by  
S = [2Tǁǁ - (2T⊥ + 1.6)] / [2Tzz – (Txx + Tyy)] 
where Txx , Tyy and Tzz are the hyperfine tensors for the nitroxide in a crystal and are assigned 
the values 6.3, 5.8 and 33.6G. In calculation of the order parameter S, a correction of 0.8 G is 
applied to the measured value of T⊥ (12,13). 
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 Cell survival assay 
Percentage of cell survival was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT) assay. MTT was purchased from Sigma–Aldrich, UK. Briefly, 
cells were treated with the indicated concentration of auranofin for 48 h. Following 1 mg/ml 
concentration of MTT was added to the wells and incubated at 37 °C for 3 h. The reaction was 
stopped with DMSO. The colour intensity was measured at 550 nm by spectrophotometry and 
relative cell viability (%) was expressed as a percentage relative to the DMSO treated control 
samples set to 100 %. 
DNA double strand breaks (DNA DSBs) analysis by immunofluorescence microscopy 
DNA damage was determined by assessing double strand breaks as reported earlier by us and 
other workers (14,15). Auranofin treated or untreated cells were  permeabilised in 0.5% 
solution of Triton X-100 in phosphate buffered saline (PBS) and then blocked with a solution 
of 0.1% Triton X-100, 10 % FBS in PBS. After blocking, cells were incubated with anti-53BP1 
rabbit polyclonal antibodies for 1 h at room temperature. Following primary antibody 
incubation, cells were washed with a 0.1% Triton X-100 in PBS washing buffer and incubated 
with Alexa Fluor 488-labeled anti-rabbit IgG secondary antibody for 1 h at room temperature. 
Cells were washed in PBS and counterstained with 4,6-diamidino-2-phenyindole (DAPI) 1 
µg/10 ml in PBS. Washed once with PBS and mounted with Fluorosave reagent (Calbiochem, 
Merck-Millipore, UK) and viewed using Zeiss Axiovert 200 M microscope (Carl Zeiss Micro 
Imaging, LLC, USA). 
Western blotting 
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Following experimental treatments, cells (0.3 x 106) were removed from the flasks by scraping. 
The whole cell lysate preparation and Western blotting were carried out as previously reported 
(14).  
Statistical analysis 
Results are reported as the mean ± SEM. Two tailed independent Student’s t test without equal 
variance assumption was used to determine p-values (*, P < 0.05; **, P < 0.005, ***, P < 
0.0005),). Significance of differences in 53BP1 foci numbers between auranofin treated 
OVCAR5 and IGROV1 cells were assessed using unpaired Student’s two-tailed t-test and 
significance of differences in 53BP1 foci numbers between auranofin treated and respective 
control cells were assessed using paired Student’s two-tailed t-test. Regression analysis was 
performed to determine the linear relationship between membrane fluidity and % cell survival.  
Analysis was performed using GraphPad Prism version 6.00 for Windows, GraphPad Software, 
La Jolla California USA, www.graphpad.com. 
Results 
Positive correlation between membrane fluidity and auranofin sensitivity: IGROV1 is more 
fluid and sensitive than OVCAR5  
The studies on membrane fluidity and chemo resistance have mainly been restricted to a single 
breast cancer cell line MCF-7 and its drug resistant variant (2).  Our aims were to do a 
comparative analysis of membrane fluidity in two ovarian cancer cell lines (OVCAR5 & 
IGROV1) of adenocarcinoma origin (16,17) and to further investigate how membrane fluidity 
influences sensitivity of these cell lines to auranofin. Electron spin resonance (ESR) using the 
spin label 5-DS allowed the determination of membrane order parameter S, which is inversely 
proportional to membrane fluidity. ESR analysis revealed relatively rigid membranes in 
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OVCAR5 as inferred by an increased S value (Figure 1A). In contrast, IGROV1 appeared to 
have a relatively fluidised membrane as demonstrated by a decreased S value (Figure 1A).   
Auranofin is known to exhibit cytotoxic activity against various cancer cells (8,9).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Assessment of viability at a wide range of concentrations showed IGROV1 cells were more 
sensitive to auranofin induced cytotoxicity than OVCAR5 cells (Figure 1 B). Treatment of 
auranofin at 1 µM resulted in more than 55 % cell death in IGROV1 compared to less than 10 % 
in OVCAR5 (Figure 1 C). Interestingly, IGROV1 possess a more fluid membrane compare to 
OVCAR5 (Figure 1 A). This prompted us to perform a correlation analysis between S values 
and % cell survival upon auranofin (1 µM) treatment. The scatter plot revealed a strong positive 
correlation (r = 0.0.856) between membrane fluidity and cell survival upon exposure to 
auranofin (1 µM). We fitted a linear regression model (R2  = 0.7319, p = 0.02982) to the data 
as demonstrated in figure 1 D. IGROV1, which possess a more fluid membrane, was more 
sensitive to auranofin than OVCAR5 with a rigid membrane (Figure 1 A, B & C). Furthermore, 
OVCAR4, another ovarian cancer cell line which also possess a relatively rigid membrane was 
comparatively resistant than IGROV1 (supplementary figure 2A & B). 
Auranofin induces increased DNA double strand breaks (DSBs) in IGROV1cells 
We have previously reported that BRCA1-depleted ovarian cancer cells exhibit increased 
sensitivity to auranofin due to the accumulation of unrepaired lethal DNA DSBs (10). In order 
to understand whether decreased survival exhibited by IGROV1 cells correlate with DNA 
damage, generation of DSBs were analysed by immunofluorescence using anti-bodies against 
53BP1. Upon double strand breaks, 53BP1 along with other DNA repair proteins relocates to 
the sites of DSBs to form discrete foci. Hence, analysing 53BP1 leads to indirect quantitative 
assessment of DSBs as reported earlier (18,19). Immunostaining of 53BP1 showed discrete 
foci marking DSBs in auranofin treated cells (Figure 2 A). As shown in the figure 2 A and B, 
10 
 
the number of foci is significantly higher in IGROV1 compared to OVCAR5 upon auranofin 
treatment. Intriguingly, there was more DSBs in untreated OVCAR5 cells and the number of 
DSBs does not significantly changed after auranofin treatment (Figure 2B). However, the 
number of cells exhibiting more than 10 foci has increased significantly after 6 h and 18 h 
following auranofin treatment of IGROV1 cells (Figure 2B).  Furthermore, auranofin induced 
DSBs were significantly higher in IGROV1 cells than OVCAR4, another ovarian cancer cell 
line which possess a comparatively rigid membrane (Supplementary figure 3).  Taken together, 
the increased number of DSBs in IGROV1 is corroborated by the decreased survival which in 
turn correlated with the increased membrane fluidity.  
Increased cellular oxidation and apoptosis in auranofin-treated IGROV1 cells 
We have reported earlier that auranofin induces oxidative stress and apoptosis in BRCA1-
depleted OVCAR5 cells. Cellular oxidative stress was determined by the expression of the 
biological marker, Nrf2 (20). Cellular oxidative stress activates Nrf2 which in turn drives the 
expression of anti-oxidant genes. As shown in figure 3 A, auranofin (1 μM) treated IGROV1 
cells exhibited strong induction of Nrf2 after 6 h compared to OVCAR5 where induction of 
Nrf2 is minimal. This suggests that auranofin causes increased cellular oxidation in IGROV1 
cells compared to OVCAR5. Western blot analysis of PARP cleavage was performed to assess 
apoptosis in auranofin-treated cancer cells. As presented in figure 3 B, there was increased 
cleavage of PARP in auranofin (2 μM) treated IGROV1 cells. On the other hand, auranofin (2 
μM) treated OVCAR5 cells exhibited less cleavage of PARP1. Overall, the data suggest that 
IGROV1 cells are comparatively more sensitive to auranofin induced cellular oxidation and 
apoptosis.  
Anti-oxidant N-Acetyl Cysteine (NAC) abrogates the cellular oxidation and apoptosis 
induced by auranofin in IGROV1 cells 
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Previous studies have established that ROS mediate the cytotoxic effects of auranofin (8). We 
also reported NAC protects BRCA1-depleted ovarian cancer cells from auranofin induced 
apoptosis (10). In order to determine whether NAC ameliorates cellular oxidation and apoptosis 
induced by auranofin, cells were pre-treated with NAC. As presented in figure 4 A, IGROV1 
cells that were pre-treated with NAC expressed less Nrf2 upon treatment with auranofin (1 
μM). However, there was no considerable decrease in Nrf2 expression when IGROV1 cells 
were treated at higher concentration (2 μM). As mentioned in the previous section, Nrf2 
expression was comparatively less in auranofin treated OVCAR5 cells. Unlike in IGROV1 
cells, OVCAR5 cells exhibited a dose dependent increase in Nrf2 expression as there was 
increased expression at higher concentration of auranofin (2 μM) compared to lower 
concentration (1 μM) (Figure 4 A). Pre-treatment with NAC blocked the expression of Nrf2 in 
OVCAR5 cells upon auranofin treatment (Figure 4 A). Interestingly, there was decreased 
cleavage of PARP in auranofin (2 μM)- treated IGROV1 cells that were pre-treated with NAC 
(Figure 4 B). This stated that NAC protects cells from apoptosis induced by auranofin (2 μM). 
On the other hand, auranofin induced less cleavage of PARP in OVCAR5 cells which was 
slightly altered by pre-treatment with NAC. 
Discussion 
Our study demonstrated that there is a positive correlation between membrane fluidity and 
auranofin sensitivity. Even though the lipid profile of IGROV1 is yet to be determined, the 
fluidic nature suggests that the membrane might consists of an increased proportion of 
unsaturated acyl side chains of phospholipids along with ceramide as reported for drug 
sensitive cancer cells (1). Conversely, the presence of large amounts of cholesterol and 
sphingomyelin rigidifies membrane and is found to be involved in developing resistance to 
various anti-cancer drugs (1). How membrane fluidity modulates drug resistance is still 
unknown and probably involves several different pathways. Drugs cross the plasma membrane 
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barrier by diffusion and diffusion rate of drugs is lower through a higher ordered rigid 
membrane compared to a lesser ordered fluid membrane (1). Pharmaceutical intervention to 
fluidise the membrane had shown that the drug could effectively diffuse into the membrane 
and could reverse the resistance (7). A rapid increase in plasma membrane fluidity has been 
reported in cisplatin treated tumour cells (21). Interestingly, in our study, auranofin does not 
induce any significant change in the membrane fluidity of ovarian cancer cell lines 
(unpublished data).  
Studies have demonstrated that membrane fluidity of cancer cells is generally greater than that 
of the normal cells and increased membrane fluidity correlates with malignant and metastatic 
potential (22) . This suggests that IGROV1 might potentially be more invasive than OVCAR5 
which possess a comparatively rigid membrane. Further studies on metastatic potential of these 
cell lines provide valuable information on the relation between membrane fluidity and the 
invasive nature of ovarian cancer cells. Interestingly, our studies with the ovarian cancer cell 
lines of the same histological origin showed that sensitivity to auranofin increases with 
membrane fluidity. Future studies investigating whether cholesterol imparts resistance to 
auranofin in IGROV1 cells strengthen our observations since cholesterol has been implicated 
in rigidifying the membrane and thereby reduces the metastatic potential of cancer cells (23).   
We have reported that the un-repaired DSBs results from auranofin treatment cause the 
increased sensitivity of BRCA1-depleted ovarian cancer cells (10). The increased number of 
DSBs in auranofin treated IGROV1 cells compared to OVCARs (OVCAR5 & OVCAR4) 
suggests that drug sensitivity correlates with DNA damage which in turn correlates with 
membrane fluidity.  Regardless of the relatively high background DNA damage in OVCAR5 
cells, the number of DSBs remained unchanged upon auranofin treatment. However, IGROV1 
exhibited a significant rise in DSBs upon auranofin treatment. Moreover, the potential of 
auranofin to cause DNA damage increases its potential as an anti-cancer drug since cancer cells 
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in general are more susceptible to DNA damaging agents due to the deregulated and faulty 
DNA repair machinery (24).  
It has been previously reported that ROS mediate the cytotoxic effects of auranofin (8). We 
also reported that anti-oxidant NAC protects BRCA1-depleted ovarian cancer cells from 
oxidative DNA damage and apoptosis induced by auranofin (10). NAC mediated inhibition of 
Nrf2 expression in auranofin (1μM) treated IGROV1 cells conclusively proved that auranofin 
induced cellular oxidation is the mechanism behind the cytotoxic effects of auranofin. This was 
further confirmed by the inhibition of apoptosis by NAC in auranofin (2μM) treated IGROV1 
cells. However, the induction of Nrf2 at higher concentration of auranofin (2μM) was not 
significantly changed in NAC pre-treated cells. Interestingly, apoptosis induced by auranofin 
at this concentration (2 μM) was blocked by NAC. This suggests that the concentration of NAC 
used in this experiment could neutralize the ROS from reaching a threshold to activate 
apoptosis. This however could not prevent the amount of ROS signalling the expression of 
Nrf2.  
In conclusion, our study suggests that there is a positive correlation between membrane fluidity 
and auranofin sensitivity in the ovarian cancer cell lines. As there is only limited information 
in the literature, more studies have to be performed with agents known to reduce membrane 
fluidity (e.g. cholesterol) to elucidate the role of membrane fluidity in modulating the 
sensitivity of malignant cells to auranofin and other drugs of interest. 
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Figure legends 
Figure 1. Auranofin sensitivity positively correlates with membrane fluidity: IGROV1 is 
more fluid and sensitive to auranofin than OVCAR5. (A) Membrane fluidity was 
determined by ESR using the spin label 5-doxyl stearic acid. Membrane order parameter S 
which is inversely proportional to the membrane fluidity was calculated from the spectra as 
mentioned in the methods. Values are the mean of three independent experiments ± SEM at 
mean temperature. S values at mean temperature were plotted. Two-tailed unpaired t test was 
performed to determine the significance difference in S values between OVCAR5 and 
IGROV1 cells.  * P<0.05.  (B)  % Cell survival was determined by MTT assay. Relative cell 
viability (%) was expressed as a percentage relative to the DMSO treated control samples set 
to 100 %. Values are the mean of three independent experiments ± SEM. ** P<0.005. (C) % 
Cell survival was determined by MTT assay. *** P<0.0005 (D) Regression analysis showing 
a positive correlation between % cell survival at 1 µM of auranofin and membrane order 
parameter S. 
Figure 2. Auranofin induces more DNA DSBs in IGROV1 cells.  (A) Immunofluorescence 
staining of 53BP1. (B) Number of cells with more than 10 53BP1 foci per 200 cells were 
counted manually per slide for each sample and the results were plotted. Data point shows the 
mean of two independent experiments ± SEM. *p < 0.05, **p < 0.005. 
Figure 3. Auranofin induces increased cellular oxidation and apoptosis in IGROV1 cells. 
(A) Expression of Nrf2 and cleavage of PARP (B) were determined by Western blotting  using 
antibodies against Nrf2 and PARP respectively.  Cells were treated with auranofin (1 µM or 2 
µM) for indicated time points and samples were processed for Western blotting.  Actin was 
determined as loading control. 
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Figure 4. Anti-oxidant N-acetyl cysteine ameliorates the cellular oxidation and apoptosis 
in auranofin-treated IGROV1 cells. Western blot analysis was performed by using antibodies 
against Nrf2 (A) PARP (B). Cells were pre-treated with NAC before treating with auranofin (2 
µM) for indicated time points and samples were processed for Western blotting. Actin was 
determined as loading control. 
 
Supplementary Figure 1. A representative ESR spectrum of 5-doxyl stearic acid spin label 
from ovarian cancer cells showing the separation of the outer extrema 2Tparallel and inner 
extrema 2Tperp. 
Supplementary Figure 2. (A) IGROV1 cells possess a more fluid membrane and exhibit 
increased sensitivity to auranofin. Membrane fluidity was determined by ESR using the 
spin label 5-doxyl stearic acid. Membrane order parameter S which is inversely proportional 
to the membrane fluidity was calculated from the spectra as mentioned in the methods. 
Values are the mean of three independent experiments ± SEM at mean temperature. S values 
at mean temperature was plotted. (B) % Cell survival was determined by MTT assay. Values 
are the mean of three independent experiments ± SEM. Two-tailed unpaired t test was 
performed to determine the significance difference in % survival between auranofin treated 
OVCAR4 and IGROV1 cells.  * P<0.05. 
Supplementary Figure 3. IGROV1 exhibits more sensitivity to auranofin induced DSBs 
than OVCAR4.  Number of cells with more than 10 53BP1 foci per 200 cells were counted 
manually per slide for each sample and plotted. Significance of differences in 53BP1 foci 
numbers between auranofin treated cells were assessed using unpaired Student’s two-tailed t-
test. Data point shows the mean of two independent experiments ± SEM. *p < 0.05. **p < 
0.005. 
